SB 1454 repeals and reenacts Missouri’s law on access to investigational drugs, biological products, and devices for patients with terminal, life-threatening, or severely debilitating conditions. The bill defines who qualifies as an eligible patient, requiring that the patient have exhausted approved FDA treatment options and relevant in-state clinical trials, receive a physician’s recommendation, and provide informed consent. It also defines the kinds of investigational therapies covered, limiting them to products that have completed phase one clinical trials but are not yet FDA-approved for general use.
The bill allows manufacturers to make these investigational therapies available to eligible patients, but it does not require them to do so. Manufacturers may provide the product without compensation or may charge the patient for manufacturing-related costs. The bill also makes clear that insurers and the Department of Corrections are not required to cover the cost of these therapies, though they may choose to do so. In addition, the bill protects physicians and other health care providers from state licensing or Medicare-certification actions based solely on recommending access to an investigational therapy.
SB 1454 would affect Missouri statutes governing medical treatment, physician discipline, and liability by creating or updating a “right-to-try” style framework for experimental treatments. It also adds a liability shield for manufacturers, distributors, prescribers, and others involved in providing the therapy, except in cases of gross negligence or willful misconduct. The bill further requires that if a clinical trial is closed for lack of efficacy or toxicity, the drug cannot be offered under this section, and it requires notice to patients if safety information emerges about a product used outside a clinical trial.
The overall sentiment reflected by the bill text is supportive of expanded patient access to experimental therapies, especially for people with serious or terminal illnesses who have limited treatment options. Because there are no committee transcripts or recorded votes provided, there is no documented public debate in the supplied materials. Based on the structure of the bill, likely areas of concern would include patient safety, informed consent, insurer and correctional-system costs, and the scope of legal protections for providers and manufacturers, but no specific opposition is shown in the available record.
The bill would amend section 191.480, RSMo, replacing the existing statutory framework for investigational therapies with a revised access-and-liability scheme. It would not compel manufacturers, insurers, or the Department of Corrections to provide or pay for investigational drugs, biological products, or devices, but it would authorize their voluntary provision and limit state regulatory action against physicians and providers who recommend them. It also expands statutory protections from civil liability for participants in the supply and treatment chain, subject to exceptions for gross negligence or willful misconduct.
The bill appears generally favorable toward patient access to experimental or alternative therapies for serious illnesses, with a patient-centered and pro-access orientation. No votes or committee testimony were provided, so there is no recorded opposition or support in the supplied history. The text itself suggests a consensus-style approach that balances access with disclaimers, consent requirements, and liability limits.
The main policy tensions in SB 1454 are between expanding access to investigational treatments and preserving safeguards around safety, efficacy, and oversight. Potentially contentious provisions include the liability shield for manufacturers and providers, the prohibition on state disciplinary action based solely on a physician’s recommendation, and the explicit statement that insurers and the Department of Corrections are not required to cover costs. Another possible point of concern is the bill’s restriction that therapies cannot be offered if a clinical trial is closed for lack of efficacy or toxicity, which reflects an effort to limit risk while still broadening access.